ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,760.47
-0.53%
Dow Jones
44,368.56
0.00%
Gold vs US Dollar
2,916.545
0.36%
Brent Oil
74.135
-0.90%
Bitcoin
95,992.78
-1.93%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Zymeworks Inc (ZYME)

  7. Zymeworks Inc (ZYME) News

Zymeworks (ZYME)

Zymeworks Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ZYME
DateTimeSourceHeadlineSymbolCompany
13/02/202511:00GlobeNewswire Inc.Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025NASDAQ:ZYMEZymeworks Inc
30/01/202511:00GlobeNewswire Inc.Zymeworks Announces Participation in Upcoming Investor ConferencesNASDAQ:ZYMEZymeworks Inc
14/01/202500:18Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:ZYMEZymeworks Inc
10/01/202523:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZYMEZymeworks Inc
08/01/202521:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZYMEZymeworks Inc
08/01/202521:05GlobeNewswire Inc.Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026NASDAQ:ZYMEZymeworks Inc
07/01/202501:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZYMEZymeworks Inc
07/01/202500:43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ZYMEZymeworks Inc
12/12/202423:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZYMEZymeworks Inc
12/12/202422:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZYMEZymeworks Inc
12/12/202422:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZYMEZymeworks Inc
12/12/202413:30GlobeNewswire Inc.Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory DiseasesNASDAQ:ZYMEZymeworks Inc
11/12/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZYMEZymeworks Inc
21/11/202421:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZYMEZymeworks Inc
21/11/202411:05GlobeNewswire Inc.Zymeworks Announces Participation in Upcoming Investor ConferencesNASDAQ:ZYMEZymeworks Inc
21/11/202411:00GlobeNewswire Inc.FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)NASDAQ:ZYMEZymeworks Inc
05/11/202411:00GlobeNewswire Inc.Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid TumorsNASDAQ:ZYMEZymeworks Inc
31/10/202420:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZYMEZymeworks Inc
31/10/202420:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZYMEZymeworks Inc
31/10/202420:05GlobeNewswire Inc.Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:ZYMEZymeworks Inc
29/10/202420:11Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ZYMEZymeworks Inc
29/10/202420:08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ZYMEZymeworks Inc
29/10/202420:06Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ZYMEZymeworks Inc
29/10/202410:00GlobeNewswire Inc.Zymeworks Announces Participation in Upcoming Investor ConferencesNASDAQ:ZYMEZymeworks Inc
25/10/202410:00GlobeNewswire Inc.Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR ConferenceNASDAQ:ZYMEZymeworks Inc
21/10/202410:00GlobeNewswire Inc.Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing CancersNASDAQ:ZYMEZymeworks Inc
18/10/202420:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZYMEZymeworks Inc
10/10/202410:30GlobeNewswire Inc.Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024NASDAQ:ZYMEZymeworks Inc
18/09/202410:00GlobeNewswire Inc.Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR ConferenceNASDAQ:ZYMEZymeworks Inc
03/09/202420:30GlobeNewswire Inc.Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)NASDAQ:ZYMEZymeworks Inc
 Showing the most relevant articles for your search:NASDAQ:ZYME

Your Recent History

BIT
F10004
Vontobel Financial Produ...
BIT
W1CALL
Meglioquesto
BIT
COMFB0
Open
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads